Literature DB >> 19010617

Effects of estrogen versus estrogen and progesterone on cortisol and interleukin-6.

Kate M Edwards1, Paul J Mills.   

Abstract

OBJECTIVES: The purpose of this study was to compare the effects of 3 months of estrogen replacement therapy, estrogen plus progesterone replacement therapy and a placebo, on the resting cortisol and interleukin-6 (IL-6) levels in post-menopausal women.
METHODS: Forty-three women were randomised to one of three treatment arms: estradiol 2mg/day (ERT), estradiol 2mg/day plus medroxyprogesterone acetate 5mg/day (HRT), or a placebo that was administered orally for 3 months.
RESULTS: Cortisol levels showed a significant condition by intervention interaction. Post hoc tests showed that ERT significantly increased cortisol levels after treatment compared to baseline, while in the HRT group a trend toward increased cortisol was found. No changes were observed in IL-6 levels.
CONCLUSIONS: Estrogen administration elevated cortisol levels, but this effect may be moderated by progestins. IL-6 was not altered by ERT or HRT, future studies should consider the interaction of cortisol increases on change in IL-6 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010617      PMCID: PMC2663529          DOI: 10.1016/j.maturitas.2008.09.024

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  32 in total

1.  Effects of estrogen replacement therapy on the circadian rhythms of serum cortisol and body temperature in postmenopausal women.

Authors:  A Gudmundsson; B Goodman; S Lent; S Barczi; A Grace; L Boyle; W B Ershler; M Carnes
Journal:  Exp Gerontol       Date:  1999-09       Impact factor: 4.032

2.  Neuroendocrine regulation of immunity.

Authors:  Jeanette I Webster; Leonardo Tonelli; Esther M Sternberg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women.

Authors:  D M Herrington; K B Brosnihan; B E Pusser; E W Seely; P M Ridker; N Rifai; D B MacLean
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

4.  Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management.

Authors:  D Zanger; B K Yang; J Ardans; M A Waclawiw; G Csako; L M Wahl; R O Cannon
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

5.  24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment.

Authors:  Nea Kalleinen; Päivi Polo-Kantola; Kerttu Irjala; Tarja Porkka-Heiskanen; Tero Vahlberg; Arho Virkki; Olli Polo
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

6.  Hormone replacement therapy increases ACTH/dehydroepiandrosterone sulfate in menopause.

Authors:  E Fonseca; L Basurto; S Velázquez; A Zárate
Journal:  Maturitas       Date:  2001-07-25       Impact factor: 4.342

7.  Inhibitory effect of physiological concentrations of cortisol but not estradiol on interleukin (IL)-6 production by human osteoblast-like cell lines with different constitutive IL-6 expression.

Authors:  A Dovio; M L Sartori; R G Masera; S Racca; A Angeli
Journal:  Cytokine       Date:  2001-07-07       Impact factor: 3.861

8.  Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study.

Authors:  R H Straub; H W Hense; T Andus; J Schölmerich; G A Riegger; H Schunkert
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

9.  Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause.

Authors:  C Scheidt-Nave; H Bismar; G Leidig-Bruckner; H Woitge; M J Seibel; R Ziegler; J Pfeilschifter
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

10.  Estrogen treatment and body fat distribution are involved in corticotropin and cortisol response to corticotropin-releasing hormone in postmenopausal women.

Authors:  Francesco Cucinelli; Liberato Soranna; Angela Barini; Concetta Perri; Fulvio Leoni; Salvatore Mancuso; Antonio Lanzone
Journal:  Metabolism       Date:  2002-02       Impact factor: 8.694

View more
  14 in total

Review 1.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.

Authors:  Durr-e-Nayab Masood; Emir C Roach; Katie G Beauregard; Raouf A Khalil
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 2.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

3.  EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone.

Authors:  Yiping Dang; Wei Li; Victoria Tran; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-07-13       Impact factor: 5.858

4.  Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.

Authors:  Kimbell L Hetzler; Justin P Hardee; Melissa J Puppa; Aditi A Narsale; Shuichi Sato; J Mark Davis; James A Carson
Journal:  Biochim Biophys Acta       Date:  2014-12-30

5.  Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones.

Authors:  Zongzhi Yin; Alaa A Sada; Ossama M Reslan; Neha Narula; Raouf A Khalil
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-04-10       Impact factor: 4.310

6.  Salivary cortisol as an alternative for serum cortisol in the low-dose adrenocorticotropic hormone stimulation test?

Authors:  R K Schindhelm; J J C M van de Leur; J M M Rondeel
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

7.  Oral contraception but not menstrual cycle phase is associated with increased free cortisol levels and low hypothalamo-pituitary-adrenal axis reactivity.

Authors:  N Boisseau; C Enea; V Diaz; B Dugué; J B Corcuff; M Duclos
Journal:  J Endocrinol Invest       Date:  2013-05-22       Impact factor: 4.256

Review 8.  The major inflammatory mediator interleukin-6 and obesity.

Authors:  Katalin Eder; Noemi Baffy; Andras Falus; Andras K Fulop
Journal:  Inflamm Res       Date:  2009-06-19       Impact factor: 4.575

9.  Interleukin-6 responses to water immersion therapy after acute exercise heat stress: a pilot investigation.

Authors:  Elaine C Lee; Greig Watson; Douglas Casa; Lawrence E Armstrong; William Kraemer; Jakob L Vingren; Barry A Spiering; Carl M Maresh
Journal:  J Athl Train       Date:  2012 Nov-Dec       Impact factor: 2.860

10.  Adiposity Measures and Morning Serum Cortisol in African Americans: Jackson Heart Study.

Authors:  Bjorn Kluwe; Songzhu Zhao; David Kline; Robin Ortiz; Guy Brock; Justin B Echouffo-Tcheugui; Mario Sims; Rita R Kalyani; Sherita H Golden; Joshua J Joseph
Journal:  Obesity (Silver Spring)       Date:  2021-02       Impact factor: 9.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.